Bacteria and Antibiotics: Revenge of the Microbes

Summary

Dr. Jenny Rohn explains how bacteria shaped life on Earth, cause disease and evade treatment, and why antibiotic resistance is becoming a serious public-health problem. Her central message is that bacteria adapt quickly, while discovering and bringing new antibiotics to patients is slow and difficult. Tackling the problem will require better use of existing drugs, new scientific approaches, and greater investment in research.

Bacteria, life, and disease

• Bacteria have existed for roughly 3.5–3.6 billion years, vastly longer than humans. Stromatolites—layered structures formed by bacterial communities—provide evidence of their ancient presence.
• Bacteria have not only been harmful. Rohn describes the theory of endosymbiosis, under which bacteria that entered early cells eventually became organelles such as mitochondria, which generate energy, and chloroplasts in plants.
• Bacteria are extraordinarily numerous, including on and inside human bodies. Some live harmlessly with us, while others cause infections.
• Evidence of ancient disease includes signs of tuberculosis in approximately 9,000-year-old remains. Rohn also recalls the devastating impact of bubonic plague, caused by Yersinia pestis.
• Humans have immune defences, but bacteria can evolve ways to avoid or undermine them. Rohn characterizes this as a continual evolutionary contest in which bacteria can adapt faster than humans can develop new defences.

How bacteria evade the immune system

Rohn uses urinary tract infections to illustrate bacterial survival strategies:

• Some E. coli can enter bladder cells and form protected intracellular communities, described as “pods.” While hidden inside cells, bacteria may be harder for immune cells and antibiotics to reach.
• These communities can later burst, releasing bacteria and restarting an acute infection.
• After emerging, some E. coli elongate into filament-like forms. Rohn describes two possible advantages:
  • Their shape may help them remain in the bladder during urination rather than being flushed out.
  • They may be harder for immune cells to engulf.
• The lecture presents these as examples of the many ways bacteria can persist despite the body’s defences.

How antibiotics work

• Before antibiotics, bacterial infections were a major cause of death. Rohn cites historical estimates that around 30% of deaths in the United States in the early 1900s involved bacterial infection or its complications.
• Penicillin was discovered after Alexander Fleming observed that mould inhibited bacterial growth in a Petri dish. Rohn emphasizes that Fleming’s discovery had to be developed into a usable medicine, with important work by Howard Florey, Ernst Chain, and their teams.
• Penicillin works by blocking an enzyme bacteria need to maintain their cell walls. Without a stable wall, the bacteria die.
• Antibiotics can target different functions essential to bacterial survival, including cell-wall maintenance, metabolism, DNA replication, and protein production.
• Rohn also highlights Selman Waksman’s work isolating antibiotics from soil microorganisms during the period of major antibiotic discovery from the 1940s to the 1960s.

How antibiotic resistance develops and spreads

• Resistance is an evolutionary process: when a drug kills susceptible bacteria, resistant ones can survive and multiply.
• Resistance is not solely a modern, human-caused phenomenon. Rohn says bacteria evolved antibiotics and resistance mechanisms long before humans existed, and that the oldest resistance gene identified in the lecture’s account dates back around 30,000 years.
• Resistance can arise through different mechanisms. For example:
  • Beta-lactamase enzymes can break open the key ring structure in penicillin-like drugs, making them ineffective.
  • MRSA can produce an alternative cell-wall enzyme, associated with the mecA gene, that penicillin-like antibiotics cannot bind effectively.
• Bacteria can acquire and share resistance genes in several ways:
  • Direct transfer of DNA between bacteria.
  • Uptake of DNA left behind when bacteria die.
  • Transfer by bacteriophages, viruses that infect bacteria.
• Resistant bacteria can also spread between people, including in healthcare settings. Some hospital strains carry multiple resistance genes together, making them resistant to several antibiotics.
• Because bacteria reproduce rapidly, they can undergo many generations—and opportunities to adapt—in a short time.

Why the problem is worsening

Rohn identifies several factors contributing to the rise of resistance:

• Inappropriate or excessive antibiotic use can give resistant bacteria an advantage. She warns that taking antibiotics when they are not needed, or not using a prescribed course as directed, can leave surviving bacteria that are harder to treat. This is the speaker’s argument in the lecture, not individual medical advice.
• Antibiotics are also used in agriculture, livestock production, and aquaculture. Rohn argues that this exposes bacteria in the wider environment to the drugs and can encourage resistance.
• The window between the introduction of an antibiotic and the appearance of resistance has shortened. The lecture says that, from around 1980, resistance to new drugs was often observed very quickly.
• Antibiotic discovery has slowed. Rohn contrasts the many classes discovered during the mid-20th-century “golden age” with the long gap in new classes that followed, noting a newly reported discovery as a possible exception.
• Developing antibiotics is difficult and costly, while the financial return can be limited: they are generally taken for short periods rather than continuously, and successful new drugs are often reserved to slow resistance. The lecture also points to regulatory obstacles and the difficulty of finding new compounds.
• Rohn cites reports of bacteria resistant to all known antibiotics and presents the possibility of untreatable infections as a growing concern.

Possible approaches and research directions

The lecture describes several strategies being explored:

• Combination treatments: Pairing a penicillin-like drug with a substance that blocks beta-lactamase can protect the antibiotic from being broken down.
• Phage therapy: Using viruses that infect bacteria as treatments. Rohn describes its use in Georgia and notes that phages may need to be updated as bacteria evolve resistance to them.
• CRISPR-Cas approaches: In principle, engineered DNA could be used to target and disable a bacterial resistance gene, allowing an antibiotic to work again. Rohn stresses that delivering such tools into bacteria remains a challenge.
• Searching beyond organisms that grow in standard laboratory conditions: Most soil microorganisms do not readily grow in the lab. The lecture describes a method that lets microbes grow in their natural environment before researchers isolate them. It led to the discovery of teixobactin, a new antibiotic reported in the lecture.
• Targeting bacterial lipids: Teixobactin acts on a lipid rather than a protein. Rohn suggests this may make resistance harder to develop, although she notes that the drug described works against Gram-positive bacteria and does not solve the problem for Gram-negative bacteria such as E. coli.
• Addressing biofilms: Bacteria often live in communities embedded in a protective slime. Biofilms can form on teeth and medical devices, impede antibiotic access, and promote the exchange of DNA. Rohn describes research with engineers to develop capsules that might penetrate biofilms.

The lecture’s closing message

• Resistance has been recognized for decades, but repeated warnings have not been matched by sufficient action.
• Rohn argues that new drugs and approaches will take sustained scientific work, and that the timeline from discovery to treatment can be long.
• She calls for greater investment in science and antibiotic research, alongside efforts to use existing antibiotics responsibly and to take the resistance problem seriously.

The subtitles end with an audience member asking why some immunocompromised patients receive preventive antibiotics without being overwhelmed by resistant bacteria. No answer to that question is included in the provided subtitles.

Speakers and sources featured

Speakers

• Dr. Jenny Rohn — lecturer and presenter.
• Unidentified audience member — asks the final question about antibiotic prophylaxis.

People, research, and sources mentioned

• Theodor Schimper and Lynn Margulis — associated with the development of the endosymbiosis theory.
• Alexander Fleming — penicillin discovery and a warning about resistance in his 1945 Nobel lecture.
• Howard Florey and Ernst Chain — work to develop penicillin for use.
• Selman Waksman — discovery and isolation of antibiotics from soil microorganisms.
• Anderson and colleagues; the Justice laboratory; and the Hultgren laboratory — research and visual examples concerning urinary tract infection, bacterial pods, and filament-shaped E. coli.
• Dave Spratt — a comparison used to illustrate the speed of bacterial evolution.
• World Health Organization and U.S. Centers for Disease Control and Prevention reports — cited in the discussion of resistance.
• A Nature paper on teixobactin — described as a new antibiotic discovery.
• The Longitude Prize, UK and EU initiatives, and U.S. Congressional efforts — mentioned in the discussion of policy and support for antibiotic research.